Form 4: Agenus Inc. CEO Garo Armen Receives Stock and Options as Part of Compensation and Retention Plan

Agenus Inc. CEO Garo Armen received stock in lieu of cash salary and a one-time retention stock option award, according to a recent SEC filing.

Summary

• Garo H. Armen, CEO of Agenus Inc., received 5,997 shares of common stock as payment for his salary for the pay period ending November 15, 2024.
• The stock was issued at a price of $2.72 per share, which was the closing price on November 15, 2024.
• Armen also received a one-time retention award of 600,000 stock options, which will vest on November 15, 2025.
• These options have an exercise price of $2.77 and expire on November 14, 2034.
• Armen also indirectly owns 108,324 shares through IRA accounts and a trust.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally positive for aligning management and shareholder interests. The use of stock in lieu of cash is a positive sign of confidence.

Positives

• The CEO's acceptance of stock in lieu of cash demonstrates confidence in the company's future.
• The retention award of stock options aligns the CEO's interests with those of shareholders.
• The vesting period of the options encourages long-term commitment from the CEO.

Risks

• The value of the stock options is dependent on the future performance of the company's stock price.
• The vesting of the options is contingent on the CEO's continued employment with the company.

Future Outlook

The document does not contain any specific forward-looking statements, but the stock option vesting date of November 15, 2025, suggests a focus on long-term performance.

Management Comments

• Garo H. Armen's salary is being paid in stock, in lieu of cash, at his request and with the approval of the Agenus Inc. Compensation Committee.
• The stock options were awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan.

Industry Context

The use of stock and stock options as part of executive compensation is a common practice in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term growth.

Comparison to Industry Standards

• Stock-based compensation is a standard practice in the biotech industry, often used to attract and retain key talent, especially in companies that are not yet profitable.
• Companies like Moderna and BioNTech also use stock options and grants as part of their executive compensation packages.
• The vesting period of one year for the options is relatively standard, although some companies may have longer or shorter vesting periods.

Stakeholder Impact

• Shareholders may view the CEO's acceptance of stock in lieu of cash as a positive sign of confidence in the company's future.
• Employees may be motivated by the retention awards, which include stock options for key personnel.

Key Dates

Keywords

Agenus Inc, Garo Armen, stock options, stock compensation, executive compensation, retention award, SEC Form 4, insider trading